BioSpace News Archive

Kaplan Fox & Kilsheimer LLP is continuing to investigate claims on behalf of investors in Spectrum Pharmaceuticals, Inc. (“Spectrum” or the “Company”) (NASDAQ: SPPI) securities.

First Wave BioPharma, Inc. announced that its Board of Directors declared a dividend of 0.001 of a share of newly-designated Series F Preferred Stock, par value $0.0001 per share, for each outstanding share of the Company’s common stock held of record as of 5:00 p.m. Eastern Time on December 5, 2022.

XORTX Therapeutics Inc. has received notification from the Nasdaq Stock Market LLC Listing Qualifications Department that it was not in compliance with the minimum bid price requirement set forth in Nasdaq Rule 5550 since the closing bid price for the Company’s common shares listed on Nasdaq was below US$1.00 for 30 consecutive business days.